Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Clinical Dermatology Open Access Journal Research Article 2 min read

Real-Life Effectiveness of Tildrakizumab in Chronic Palmo- Plantar Psoriasis: A Case Series of 7 Patients with 28 weeks of Follow-Up

Ariasi C, Licata G*, Romano C, Bettolini L, Mezzana S, Maione V, Calzavara-Pinton PG and Arisi MC
* Corresponding author
ISSN: 2574-7800  10.23880/cdoaj-16000299  Received: May 08, 2023  Published: May 17, 2023
 — views
 10 references
 1 figure
 1 table
PDF
Keywords
Psoriasis Palmo-Plantar Psoriasis Tildrakizumab Biologics Psoriasis Treatment
Abstract

Palmo-plantar psoriasis (PPP) is highly debilitating and difficult to treat impairing quality of life of patients. Tildrakizumab is an anti-IL23p19 subunit monoclonal antibody approved for the treatment of moderate-severe chronic plaque psoriasis in adult candidates for systemic therapy. Objective of this study is to investigate the safety and efficacy of tildrakizumab in the management of palmo-plantar psoriasis. A total of 7 adults patients with moderate to severe PPP were retrospective analysed. Tildrakizumab 100 mg was administered at weeks 0, 4 and then every 12 weeks, by subcutaneous injection. Patients were visited at baseline, at week 16 and at week 28. Safety and efficacy were assessed at weeks 0, 16 and 28. Physician's Global Assessment (PGA) and Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) clinical score were used to measure the efficacy. The mean PGA score was reduced from 3.6 at baseline to 1.7 after 16 weeks and 1.3 after 28 weeks. The mean PPPASI score was reduced from 19.2 at baseline to 9.2 after 16 weeks and 5.2 after 28 weeks. In conclusion tildrakizumab represents a safe and effective treatment for psoriasis even in difficult areas such as the palms and soles.

Figures

Figure 1: Palmo-plantar psoriasis in a 62-year-old women at the baseline (a,c), after 16 weeks (b,d) and after 28 weeks (e,f) of therapy with tildrakizumab. Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) dropped from 21.6 to 10.2 after 16 weeks and to 2.4 after 28 weeks.
Click to enlarge
Figure 1: Palmo-plantar psoriasis in a 62-year-old women at the baseline (a,c), after 16 weeks (b,d) and after 28 weeks (e,f) of therapy with tildrakizumab. Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) dropped from 21.6 to 10.2 after 16 weeks and to 2.4 after 28 weeks.

Tables

AgeSexHistory of
Psoriasis		Previous therapyPPPASI
T0		PGA
T0		PPPASI
T1		PGA
T1		PPPASI
T2		PGA
T2
56F3yCyclosporine, Acitretin15.23823.61
51F12yBath-PUVA, Cyclosporine, Methotrexate12.138.427.92
62F9yControindicatons to systemic therapy21.6410.222.41
63M8yAcitretin1325.615.21
39F2yCyclosporine2547.8151
49M7yNB-UVB Phototherapy, Secukinumab,
Etanercept, Risankizumab		23.6411.629.62
52M2yAcitretin24512.822.41

Table 1: Characteristics and changes of values of Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI), Physician’s G

References

  1. Okubo Y, Morishima H, Zheng R, Terui T (2021) Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study. J Dermatol 48(12): 1838- 1853.
  2. Sanchez IM, Sorenson E, Levin E, Liao W (2017) The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review. Dermatol Ther (Heidelb) 7(4): 425- 446.
  3. Gerdes S, Franke J, Domm S, Mrowietz U (2010) Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 163(5): 1116-1118.
  4. Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, et al. (2022) Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat 33(6): 2813-2820.
  5. Gottlieb ASJ, Dorn VM (2015) Secukinumab efficacy and safety in subjects with moderate to severe palmoplantar psoriasis in a phase 3b study (GESTURE). 23rd World Congress of Dermatology; Vancouver, pp: 8-13.
  6. Reich K (2016) Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER-2. In: 74th Annual Meeting of the American Academy of Dermatology; Washington, DC.
  7. Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, et al. (2017) Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol 31(10): 1686-1692.
  8. Galluzzo M, Talamonti M, Cioni A, Maffei V, Shumak RG, et al. (2022) Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med 11(9): 2631.
  9. Gambardella A, Licata G, Tancredi V, Calabrese G, Rosa ADE, et al. (2022) A case of refractory palmoplantar psoriasis treated with tildrakizumab. Ital J Dermatol Venereol 157(4): 379-80.
  10. Licata G, Danzuso GCL, Fiorella C, Palazzo G, Calzavara- Pinton P, et al. (2022) Efficacy, safety and patient’s satisfaction for treatment of genital psoriasis with tildrakizumab: a case series and review of literature. J Eur Acad Dermatol Venereol 36(11): 916-918.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{ariasi2023,
  title   = {Real-Life Effectiveness of Tildrakizumab in Chronic Palmo-
Plantar Psoriasis: A Case Series of 7 Patients with 28 weeks of
Follow-Up},
  author  = {Ariasi C, Licata G, Romano C, Bettolini L, Mezzana S, Maione V, Calzavara-Pinton PG and Arisi MC},
  journal = {Clinical Dermatology Open Access Journal},
  year    = {2023},
  volume  = {8},
  number  = {2},
  doi     = {10.23880/cdoaj-16000299}
}
Ariasi C, Licata G, Romano C, Bettolini L, Mezzana S, Maione V, Calzavara-Pinton PG and Arisi MC (2023). Real-Life Effectiveness of Tildrakizumab in Chronic Palmo-
Plantar Psoriasis: A Case Series of 7 Patients with 28 weeks of
Follow-Up. Clinical Dermatology Open Access Journal, 8(2). https://doi.org/10.23880/cdoaj-16000299
TY  - JOUR
TI  - Real-Life Effectiveness of Tildrakizumab in Chronic Palmo-
Plantar Psoriasis: A Case Series of 7 Patients with 28 weeks of
Follow-Up
AU  - Ariasi C, Licata G, Romano C, Bettolini L, Mezzana S, Maione V, Calzavara-Pinton PG and Arisi MC
JO  - Clinical Dermatology Open Access Journal
PY  - 2023
VL  - 8
IS  - 2
DO  - 10.23880/cdoaj-16000299
ER  -